keyword
https://read.qxmd.com/read/36190341/effects-of-different-routes-of-administration-and-doses-of-sulodexide-on-leukocyte-endothelium-interaction-and-tissue-perfusion-on-an-animal-model-of-low-flow-and-high-pressure-in-veins
#21
JOURNAL ARTICLE
Maria das Graças Coelho de Souza, Iasmim Bento Leal, Fatima Zely Garcia de Almeida Cyrino, Eliete Bouskela
OBJECTIVES: To assess the effects of different doses and routes of Sulodexide on leukocyte-endothelium interaction and tissue perfusion in a model of venous hypertension and low blood flow. METHODS: Six weeks after venous hypertension induction, through external iliac vein ligature male hamsters ( Mesocricetus auratus ) received Sulodexide at 1, 2, or 4 mg/kg/day or saline (placebo) by subcutaneous or intramuscular routes during 2 or 4 weeks. After treatments, leukocyte rolling and adhesion, functional capillary density (FCD), and venular diameter were evaluated on the affected hindlimb...
December 2022: Phlebology
https://read.qxmd.com/read/36080234/sulodexide-increases-glutathione-synthesis-and-causes-pro-reducing-shift-in-glutathione-redox-state-in-huvecs-exposed-to-oxygen-glucose-deprivation-implication-for-protection-of-endothelium-against-ischemic-injury
#22
JOURNAL ARTICLE
Klaudia Bontor, Bożena Gabryel
Sulodexide (SDX), a purified glycosaminoglycan mixture used to treat vascular diseases, has been reported to exert endothelial protective effects against ischemic injury. However, the mechanisms underlying these effects remain to be fully elucidated. The emerging evidence indicated that a relatively high intracellular concentration of reduced glutathione (GSH) and a maintenance of the redox environment participate in the endothelial cell survival during ischemia. Therefore, the aim of the present study was to examine the hypothesis that SDX alleviates oxygen-glucose deprivation (OGD)-induced human umbilical endothelial cells' (HUVECs) injury, which serves as the in vitro model of ischemia, by affecting the redox state of the GSH: glutathione disulfide (GSSG) pool...
August 25, 2022: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/36060145/the-protective-effect-of-sulodexide-on-acute-lung-injury-induced-by-a-murine-model-of-obstructive-jaundice
#23
JOURNAL ARTICLE
Penglei Ma, Yue Long, Qiang Fu, Yanhong Liu, Yitian Yang, Weixing Zhao, Qiangwei Liu, Yang Li, Weidong Mi
Introduction: The effect of sulodexide (SLX) on obstructive jaundice- (OJ-) induced acute lung injury (ALI) in rats was examined in this study. Methods: In this study, 48 rats were randomly assigned to one of six groups: sham, OJ, OJ+saline, OJ+SLX (0.5 mg/ml/d), OJ+SLX (1 mg/ml/d), and OJ+SLX (2 mg/ml/d). The pathological lung injury was assessed by histological analysis and lung injury grading. ELISA kits were used to evaluate the expression of IL-6, IL-1, TNF- α , and syndecan-1 (SDC-1) in bronchoalveolar lavage fluids (BALFs)...
2022: BioMed Research International
https://read.qxmd.com/read/35988926/pharmacological-protection-of-vascular-endothelium-in-acute-covid-19
#24
REVIEW
K Bednarz, A Borek, F Drzymala, K Rachwal, B Gabryel
Since the beginning of the COVID-19 pandemic, there has been an urgent need to find effective treatment. It is widely known that virus attacks and damages mostly the lungs, but also infect vascular endothelial cells. Therefore, the protection of the endothelium is a promising target in the therapy of COVID-19 and its complications. In this review article, we focused on several groups of drugs with potential to protect the endothelium. The most promising ones are angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, drugs targeting angiotensin-converting enzyme 2, heparins, sulodexide, acetylsalicylic acid, statins, tocilizumab, baricitinib, and defibrotide...
April 2022: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://read.qxmd.com/read/35906716/isth-guidelines-for-antithrombotic-treatment-in-covid-19
#25
JOURNAL ARTICLE
Sam Schulman, Michelle Sholzberg, Alex C Spyropoulos, Ryan Zarychanski, Helaine E Resnick, Charlotte A Bradbury, Lisa Broxmeyer, Jean Marie Connors, Anna Falanga, Toshiaki Iba, Scott Kaatz, Jerrold H Levy, Saskia Middeldorp, Tracy Minichiello, Eduardo Ramacciotti, Charles Marc Samama, Jecko Thachil
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants and antiplatelet agents for patients with COVID-19 in different clinical settings...
October 2022: Journal of Thrombosis and Haemostasis: JTH
https://read.qxmd.com/read/35647070/sulodexide-significantly-improves-endothelial-dysfunction-and-alleviates-chest-pain-and-palpitations-in-patients-with-long-covid-19-insights-from-tun-endcov-study
#26
JOURNAL ARTICLE
Salma Charfeddine, Hassen Ibnhadjamor, Jihen Jdidi, Slim Torjmen, Salma Kraiem, Amine Bahloul, Ahmed Makni, Nesrine Kallel, Nedia Moussa, Mariem Boudaya, Imen Touil, Aiman Ghrab, Jamel Elghoul, Zeineb Meddeb, Yamina Thabet, Kais Ben Salem, Faouzi Addad, Kamel Bouslama, Sami Milouchi, Rania Hammami, Salem Abdessalem, Leila Abid
Objective: Non-respiratory long-coronavirus disease 2019 (COVID-19) symptoms are mainly related to a long-lasting endothelial dysfunction and microcirculation impairment. We hypothesized that Sulodexide, a purified glycosaminoglycan mixture with a beneficial endothelial effect in arterial and venous peripheral diseases, may be effective in a subset of patients with long COVID-19. Approach and Results: We conducted a multicenter prospective quasi-experimental study...
2022: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/35566614/raynaud-s-phenomenon-with-focus-on-systemic-sclerosis
#27
REVIEW
Magdalena Maciejewska, Mariusz Sikora, Cezary Maciejewski, Rosanna Alda-Malicka, Joanna Czuwara, Lidia Rudnicka
Raynaud's phenomenon is a painful vascular condition in which abnormal vasoconstriction of the digital arteries causes blanching of the skin. The treatment approach can vary depending on the underlying cause of disease. Raynaud's phenomenon can present as a primary symptom, in which there is no evidence of underlying disease, or secondary to a range of medical conditions or therapies. Systemic sclerosis is one of the most frequent causes of secondary Raynaud's phenomenon; its appearance may occur long before other signs and symptoms...
April 28, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/35407602/effect-of-sulodexide-on-circulating-blood-cells-in-patients-with-mild-covid-19
#28
JOURNAL ARTICLE
Arthur Melkumyants, Lyudmila Buryachkovskaya, Nikita Lomakin, Olga Antonova, Julia Docenko, Vladimir Ermishkin, Victor Serebruany
BACKGROUND: Despite the fact that COVID-19 usually manifests with severe pneumonia, there is a growing body of evidence that life-threatening multiorgan damage is caused by vascular and hemostatic abnormalities. Since there is no established therapy, assessing antithrombotics is indeed important. Sulodexide, a compound derived from porcine intestinal mucosa is a mixture of fast-moving heparin fraction (80%) and dermatan sulfate (20%), is approved in Europe and currently in trials for COVID-19 indication...
April 2, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/35322889/cardiovascular-drugs-and-covid-19-clinical-outcomes-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#29
REVIEW
Innocent G Asiimwe, Sudeep P Pushpakom, Richard M Turner, Ruwanthi Kolamunnage-Dona, Andrea L Jorgensen, Munir Pirmohamed
AIMS: To update our previously reported systematic review and meta-analysis of observational studies on cardiovascular drug exposure and COVID-19 clinical outcomes by focusing on newly published randomized controlled trials (RCTs). METHODS: More than 500 databases were searched between 1 November 2020 and 2 October 2021 to identify RCTs that were published after our baseline review. One reviewer extracted data with other reviewers verifying the extracted data for accuracy and completeness...
August 2022: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/35100955/management-of-post-thrombotic-syndrome-a-comprehensive-review
#30
REVIEW
Nikolaos Chaitidis, Damianos G Kokkinidis, Zoi Papadopoulou, Natasha Hasemaki, Robert Attaran, Christos Bakoyiannis
BACKGROUND: Post-thrombotic syndrome (PTS) is the most common long-term complication of acute deep venous thrombosis (DVT). The cumulative incidence of PTS in the first two years after the first acute DVT diagnosis approximates 25%. OBJECTIVE: This study aims to summarize the most recent updates and provide a comprehensive review of the current management of PTS. METHODS: We searched MEDLINE/PMC/NCBI Bookshelf (PubMed), Cochrane, Embase, Scopus, ClinicalTrials, and OpenGrey databases for relevant articles in English published from the establishment of each separate database until February 9, 2021...
2022: Current Pharmaceutical Design
https://read.qxmd.com/read/34841907/anticoagulation-duration-after-first-venous-thromboembolism-real-life-data-from-the-international-observational-white-study
#31
MULTICENTER STUDY
Gualtiero Palareti, Angelo A Bignamini, Michela Cini, Young-Jun Li, Tomasz Urbanek, Juraj Madaric, Kamel Bouslama, German Y Sokurenko, Giuseppe M Andreozzi, Jiří Matuška, Armando Mansilha, Victor Barinov
BACKGROUND: International guidelines recommend at least three months anticoagulation in all patients after acute venous thromboembolism (VTE) and suggest those with unprovoked events be considered for indefinite anticoagulation if the risk of recurrence is high and the risk of bleeding during treatment non-high. Other authors have recently argued against using a dichotomy unprovoked/provoked events to decide on anticoagulation duration and suggest instead using overall risk factors present in each patient as the basis for deciding...
January 2021: Clinical and Applied Thrombosis/hemostasis
https://read.qxmd.com/read/34611615/efficacy-of-pharmacologic-treatment-in-tinnitus-patients-without-specific-or-treatable-origin-a-network-meta-analysis-of-randomised-controlled-trials
#32
JOURNAL ARTICLE
Jiann-Jy Chen, Yen-Wen Chen, Bing-Yan Zeng, Chao-Ming Hung, Bing-Syuan Zeng, Brendon Stubbs, Andre F Carvalho, Trevor Thompson, Michael Roerecke, Kuan-Pin Su, Yu-Kang Tu, Yi-Cheng Wu, Lee Smith, Tien-Yu Chen, Pao-Yen Lin, Chih-Sung Liang, Chih-Wei Hsu, Shih-Pin Hsu, Hung-Chang Kuo, Ming-Kung Wu, Ping-Tao Tseng
BACKGROUND: Although tinnitus has a prevalence between 20 and 42.8%, the currently recommended management for tinnitus, such as tinnitus support and psychologic therapies, are relatively time-consuming and expensive. Several new pharmacologic treatments designed for tinnitus patients without specific origin had been developed but their efficacy remains unclear. METHODS: The current Network Meta-Analysis (NMA) of randomised controlled trials (RCTs) was conducted to evaluate the efficacy of different pharmacologic treatments for tinnitus management in tinnitus patients without specific or treatable origin (i...
September 2021: EClinicalMedicine
https://read.qxmd.com/read/34497655/sulodexide-prevents-peritoneal-fibrosis-by-downregulating-the-expression-of-tgf-%C3%AE-1-and-its-signaling-pathway-molecules
#33
JOURNAL ARTICLE
Zhiqiang Duan, Jia Yao, Nan Duan, Min Wang, Shiwei Wang
Peritoneal dialysis is one of the main renal replacement treatments. However, long-term peritoneal dialysis keeps the peritoneum in contact with the sugar-containing nonphysiological peritoneal fluid, which leads to recurrent peritonitis, peritoneal fibrosis, and failure of ultrafiltration. Transforming growth factor- β 1 (TGF- β 1), related cytokines, and inflammatory factors are closely related to peritoneal fibrosis. Sulodexide (SLX) is a new type of glycosaminoglycan preparation, which is involved in the formation of an anionic charge barrier and can maintain the selective permeability of vascular endothelial cells...
2021: Evidence-based Complementary and Alternative Medicine: ECAM
https://read.qxmd.com/read/34313959/unprovoked-or-provoked-venous-thromboembolism-not-the-prevalent-criterion-to-decide-on-anticoagulation-extension-in-clinical-practice-of-various-countries-the-prospective-international-observational-white-study
#34
JOURNAL ARTICLE
Gualtiero Palareti, Angelo Bignamini, Michela Cini, Young-Jun Li, Tomasz Urbanek, Juraj Madaric, Kamel Bouslama, German Y Sokurenko, Giuseppe M Andreozzi, Jiří Matuška, Armando Mansilha, Victor Barinov
The decision on treatment after a first venous thromboembolism (VTE) to prevent recurrences may be influenced by many factors. The prospective, observational, WHITE study aimed to analyze how this issue was tackled in every-day clinical practice in various countries, which have sensibly different socio-economic conditions and healthcare systems. Doctors active in 79 Internal or Vascular clinical centers in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia) enrolled VTE patients after the maintenance treatment phase...
January 2022: Internal and Emergency Medicine
https://read.qxmd.com/read/34250453/mechanisms-of-lower-extremity-vein-dysfunction-in-chronic-venous-disease-and-implications-in-management-of-varicose-veins
#35
JOURNAL ARTICLE
Joseph D Raffetto, Raouf A Khalil
Chronic venous disease (CVD) is a common venous disorder of the lower extremities. CVD can be manifested as varicose veins (VVs), with dilated and tortuous veins, dysfunctional valves and venous reflux. If not adequately treated, VVs could progress to chronic venous insufficiency (CVI) and lead to venous leg ulcer (VLU). Predisposing familial and genetic factors have been implicated in CVD. Additional environmental, behavioral and dietary factors including sedentary lifestyle and obesity may also contribute to CVD...
2021: Vessel Plus
https://read.qxmd.com/read/34157890/interventions-in-an-ambulatory-setting-to-prevent-progression-to-severe-disease-in-patients-with-covid-19-a-systematic-review
#36
JOURNAL ARTICLE
Eamon O Murchu, Susan Spillane, Paula Byrne, Michelle O'Neill, Patricia Harrington, Máirín Ryan
OBJECTIVE: To conduct a systematic review on the effectiveness and safety of pharmacological and nonpharmacological interventions, in the ambulatory setting, aimed at preventing severe disease in patients with COVID-19. DATA SOURCES: Electronic databases (PubMed, EMBASE, and EuropePMC) were searched on January 6, 2021. STUDY SELECTION AND DATA EXTRACTION: A systematic review was conducted, adhering to PRISMA guidelines. The quality of individual trials was assessed using the Cochrane Risk-of-Bias Tool 2, and the certainty of evidence was assessed using GRADE...
June 22, 2021: Annals of Pharmacotherapy
https://read.qxmd.com/read/34075143/sulodexide-reduces-glucose-induced-senescence-in-human-retinal-endothelial-cells
#37
JOURNAL ARTICLE
A Gericke, K Suminska-Jasińska, A Bręborowicz
Chronic exposure of retinal endothelium cells to hyperglycemia is the leading cause of diabetic retinopathy. We evaluated the effect of high glucose concentration on senescence in human retinal endothelial cells (HREC) and modulation of that effect by Sulodexide. Experiments were performed on HREC undergoing in vitro replicative senescence in standard medium or medium supplemented with glucose 20 mmol/L (GLU) or mannitol 20 mnol/L (MAN). Effect of Sulodexide 0.5 LRU/mL (SUL) on the process of HREC senescence was studied...
June 1, 2021: Scientific Reports
https://read.qxmd.com/read/33983078/systematic-literature-review-and-network-meta-analysis-of-sulodexide-and-other-drugs-in-chronic-venous-disease
#38
JOURNAL ARTICLE
Giuseppe Pompilio, Andrew Nicolaides, Stavros K Kakkos, Davide Integlia
OBJECTIVE: To assess the clinical efficacy of sulodexide, including a comparison with venoactive drugs (VAD) (micronized purified flavonoid fraction, MPFF; hydroxy-ethyl-rutosides, HR; calcium dobesilate;Ruscus extract combined with hesperidin methyl chalcone and vitamin C, Ruscus+HMC+VitC; horse chestnut seed extract, HCSE) and pentoxifylline in patients with chronic venous disease. METHODS: We performed a literature search in MEDLINE, Embase, and Cochrane Library for randomized controlled trials (RCTs) and observational studies...
October 2021: Phlebology
https://read.qxmd.com/read/33911794/a-case-of-livedoid-vasculopathy-successfully-treated-with-sulodexide
#39
Chang Hwa Song, Dong Seok Shin, Ju Wang Jang, Tae Lim Kim, Young Gyun Kim, Joung Soo Kim, Hyun-Min Seo
We report a 29-year-old female with a one-month history of non-healing multiple erythematous to violaceous plaques with crusts over both legs and feet. Tender, scarring ulcers with surrounding erythema were present. The clinical manifestation, together with histopathologic findings of fibrinoid plugs within vascular lumens and walls, as well as red blood cell extravasation, led to diagnosis of livedoid vasculopathy. The patient experienced recurrent painful violaceous plaques with ulcerations during the two years of treatment with oral pentoxifylline 400 mg three times daily...
December 2020: Annals of Dermatology
https://read.qxmd.com/read/33831961/anticoagulant-treatment-of-covid-19-as-early-as-possible-sulodexide-and-perspectives
#40
EDITORIAL
Sam Schulman, Job Harenberg
No abstract text is available yet for this article.
July 2021: Thrombosis and Haemostasis
keyword
keyword
9297
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.